ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Next-Generation Gynecological Cancer Diagnostics Market Research Report 2024
Published Date: May 2024
|
Report Code: QYRE-Auto-14F11235
Home | Market Reports | Health| Health Conditions| Cancer
Global Next Generation Gynecological Cancer Diagnostics Market Research Report 2022
BUY CHAPTERS

Global Next-Generation Gynecological Cancer Diagnostics Market Research Report 2024

Code: QYRE-Auto-14F11235
Report
May 2024
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc
Agilent Technologies Inc
Invitae Corporation
Konica Minolta Inc
BGI Genomics
CENTOGENE N.V
Fulgent Genetics Inc
Illumina Inc
F Hoffmann La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics Inc
OPKO Health Inc
QIAGEN N V

Next-Generation Gynecological Cancer Diagnostics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Next-Generation Gynecological Cancer Diagnostics Market

Next-Generation Gynecological Cancer Diagnostics Market

The global Next-Generation Gynecological Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Next-Generation Gynecological Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Gynecological Cancer Diagnostics.

Report Scope

The Next-Generation Gynecological Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Next-Generation Gynecological Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next-Generation Gynecological Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Next-Generation Gynecological Cancer Diagnostics Market Report

Report Metric Details
Report Name Next-Generation Gynecological Cancer Diagnostics Market
CAGR 5%
Segment by Type
  • Ovarian Cancer Diagnosis
  • Cervical Cancer Diagnosis
  • Uterine Cancer Diagnosis
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Invitae Corporation, Konica Minolta, Inc., BGI Genomics, CENTOGENE N.V., Fulgent Genetics, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings, ARUP Laboratories, Myriad Genetics, Inc., OPKO Health, Inc., QIAGEN N.V.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Next-Generation Gynecological Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Next-Generation Gynecological Cancer Diagnostics Market report?

Ans: The main players in the Next-Generation Gynecological Cancer Diagnostics Market are Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Invitae Corporation, Konica Minolta, Inc., BGI Genomics, CENTOGENE N.V., Fulgent Genetics, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings, ARUP Laboratories, Myriad Genetics, Inc., OPKO Health, Inc., QIAGEN N.V.

What are the Application segmentation covered in the Next-Generation Gynecological Cancer Diagnostics Market report?

Ans: The Applications covered in the Next-Generation Gynecological Cancer Diagnostics Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Next-Generation Gynecological Cancer Diagnostics Market report?

Ans: The Types covered in the Next-Generation Gynecological Cancer Diagnostics Market report are Ovarian Cancer Diagnosis, Cervical Cancer Diagnosis, Uterine Cancer Diagnosis

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Ovarian Cancer Diagnosis
1.2.3 Cervical Cancer Diagnosis
1.2.4 Uterine Cancer Diagnosis
1.3 Market by Application
1.3.1 Global Next-Generation Gynecological Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Perspective (2019-2030)
2.2 Next-Generation Gynecological Cancer Diagnostics Growth Trends by Region
2.2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Next-Generation Gynecological Cancer Diagnostics Market Dynamics
2.3.1 Next-Generation Gynecological Cancer Diagnostics Industry Trends
2.3.2 Next-Generation Gynecological Cancer Diagnostics Market Drivers
2.3.3 Next-Generation Gynecological Cancer Diagnostics Market Challenges
2.3.4 Next-Generation Gynecological Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Next-Generation Gynecological Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next-Generation Gynecological Cancer Diagnostics Revenue
3.4 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Gynecological Cancer Diagnostics Revenue in 2023
3.5 Next-Generation Gynecological Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Next-Generation Gynecological Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Next-Generation Gynecological Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Type
4.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Application
5.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Next-Generation Gynecological Cancer Diagnostics Market Size (2019-2030)
6.2 North America Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next-Generation Gynecological Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Quest Diagnostics Incorporated
11.1.1 Quest Diagnostics Incorporated Company Detail
11.1.2 Quest Diagnostics Incorporated Business Overview
11.1.3 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Introduction
11.1.4 Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.1.5 Quest Diagnostics Incorporated Recent Development
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Detail
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.2.5 Thermo Fisher Scientific Inc. Recent Development
11.3 Agilent Technologies, Inc.
11.3.1 Agilent Technologies, Inc. Company Detail
11.3.2 Agilent Technologies, Inc. Business Overview
11.3.3 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.3.4 Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.3.5 Agilent Technologies, Inc. Recent Development
11.4 Invitae Corporation
11.4.1 Invitae Corporation Company Detail
11.4.2 Invitae Corporation Business Overview
11.4.3 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Introduction
11.4.4 Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.4.5 Invitae Corporation Recent Development
11.5 Konica Minolta, Inc.
11.5.1 Konica Minolta, Inc. Company Detail
11.5.2 Konica Minolta, Inc. Business Overview
11.5.3 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.5.4 Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.5.5 Konica Minolta, Inc. Recent Development
11.6 BGI Genomics
11.6.1 BGI Genomics Company Detail
11.6.2 BGI Genomics Business Overview
11.6.3 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Introduction
11.6.4 BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.6.5 BGI Genomics Recent Development
11.7 CENTOGENE N.V.
11.7.1 CENTOGENE N.V. Company Detail
11.7.2 CENTOGENE N.V. Business Overview
11.7.3 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
11.7.4 CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.7.5 CENTOGENE N.V. Recent Development
11.8 Fulgent Genetics, Inc.
11.8.1 Fulgent Genetics, Inc. Company Detail
11.8.2 Fulgent Genetics, Inc. Business Overview
11.8.3 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.8.4 Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.8.5 Fulgent Genetics, Inc. Recent Development
11.9 Illumina, Inc.
11.9.1 Illumina, Inc. Company Detail
11.9.2 Illumina, Inc. Business Overview
11.9.3 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.9.4 Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.9.5 Illumina, Inc. Recent Development
11.10 F. Hoffmann-La Roche Ltd
11.10.1 F. Hoffmann-La Roche Ltd Company Detail
11.10.2 F. Hoffmann-La Roche Ltd Business Overview
11.10.3 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Introduction
11.10.4 F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.10.5 F. Hoffmann-La Roche Ltd Recent Development
11.11 Laboratory Corporation of America Holdings
11.11.1 Laboratory Corporation of America Holdings Company Detail
11.11.2 Laboratory Corporation of America Holdings Business Overview
11.11.3 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Introduction
11.11.4 Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.11.5 Laboratory Corporation of America Holdings Recent Development
11.12 ARUP Laboratories
11.12.1 ARUP Laboratories Company Detail
11.12.2 ARUP Laboratories Business Overview
11.12.3 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Introduction
11.12.4 ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.12.5 ARUP Laboratories Recent Development
11.13 Myriad Genetics, Inc.
11.13.1 Myriad Genetics, Inc. Company Detail
11.13.2 Myriad Genetics, Inc. Business Overview
11.13.3 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.13.4 Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.13.5 Myriad Genetics, Inc. Recent Development
11.14 OPKO Health, Inc.
11.14.1 OPKO Health, Inc. Company Detail
11.14.2 OPKO Health, Inc. Business Overview
11.14.3 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
11.14.4 OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.14.5 OPKO Health, Inc. Recent Development
11.15 QIAGEN N.V.
11.15.1 QIAGEN N.V. Company Detail
11.15.2 QIAGEN N.V. Business Overview
11.15.3 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
11.15.4 QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
11.15.5 QIAGEN N.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc
Agilent Technologies Inc
Invitae Corporation
Konica Minolta Inc
BGI Genomics
CENTOGENE N.V
Fulgent Genetics Inc
Illumina Inc
F Hoffmann La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics Inc
OPKO Health Inc
QIAGEN N V
List of Tables
    Table 1. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Ovarian Cancer Diagnosis
    Table 3. Key Players of Cervical Cancer Diagnosis
    Table 4. Key Players of Uterine Cancer Diagnosis
    Table 5. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2019-2024)
    Table 9. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2025-2030)
    Table 11. Next-Generation Gynecological Cancer Diagnostics Market Trends
    Table 12. Next-Generation Gynecological Cancer Diagnostics Market Drivers
    Table 13. Next-Generation Gynecological Cancer Diagnostics Market Challenges
    Table 14. Next-Generation Gynecological Cancer Diagnostics Market Restraints
    Table 15. Global Next-Generation Gynecological Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players (2019-2024)
    Table 17. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2023)
    Table 18. Ranking of Global Top Next-Generation Gynecological Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
    Table 19. Global 5 Largest Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Next-Generation Gynecological Cancer Diagnostics Product Solution and Service
    Table 22. Date of Enter into Next-Generation Gynecological Cancer Diagnostics Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2019-2024)
    Table 26. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2025-2030)
    Table 28. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2019-2024)
    Table 30. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2025-2030)
    Table 32. North America Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 33. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
    Table 34. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
    Table 35. Europe Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
    Table 37. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 39. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
    Table 40. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
    Table 41. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 42. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
    Table 43. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
    Table 44. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
    Table 47. Quest Diagnostics Incorporated Company Detail
    Table 48. Quest Diagnostics Incorporated Business Overview
    Table 49. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Product
    Table 50. Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 51. Quest Diagnostics Incorporated Recent Development
    Table 52. Thermo Fisher Scientific Inc. Company Detail
    Table 53. Thermo Fisher Scientific Inc. Business Overview
    Table 54. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 55. Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 56. Thermo Fisher Scientific Inc. Recent Development
    Table 57. Agilent Technologies, Inc. Company Detail
    Table 58. Agilent Technologies, Inc. Business Overview
    Table 59. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 60. Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 61. Agilent Technologies, Inc. Recent Development
    Table 62. Invitae Corporation Company Detail
    Table 63. Invitae Corporation Business Overview
    Table 64. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Product
    Table 65. Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 66. Invitae Corporation Recent Development
    Table 67. Konica Minolta, Inc. Company Detail
    Table 68. Konica Minolta, Inc. Business Overview
    Table 69. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 70. Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 71. Konica Minolta, Inc. Recent Development
    Table 72. BGI Genomics Company Detail
    Table 73. BGI Genomics Business Overview
    Table 74. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Product
    Table 75. BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 76. BGI Genomics Recent Development
    Table 77. CENTOGENE N.V. Company Detail
    Table 78. CENTOGENE N.V. Business Overview
    Table 79. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Product
    Table 80. CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 81. CENTOGENE N.V. Recent Development
    Table 82. Fulgent Genetics, Inc. Company Detail
    Table 83. Fulgent Genetics, Inc. Business Overview
    Table 84. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 85. Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 86. Fulgent Genetics, Inc. Recent Development
    Table 87. Illumina, Inc. Company Detail
    Table 88. Illumina, Inc. Business Overview
    Table 89. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 90. Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 91. Illumina, Inc. Recent Development
    Table 92. F. Hoffmann-La Roche Ltd Company Detail
    Table 93. F. Hoffmann-La Roche Ltd Business Overview
    Table 94. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Product
    Table 95. F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 96. F. Hoffmann-La Roche Ltd Recent Development
    Table 97. Laboratory Corporation of America Holdings Company Detail
    Table 98. Laboratory Corporation of America Holdings Business Overview
    Table 99. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Product
    Table 100. Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 101. Laboratory Corporation of America Holdings Recent Development
    Table 102. ARUP Laboratories Company Detail
    Table 103. ARUP Laboratories Business Overview
    Table 104. ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Product
    Table 105. ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 106. ARUP Laboratories Recent Development
    Table 107. Myriad Genetics, Inc. Company Detail
    Table 108. Myriad Genetics, Inc. Business Overview
    Table 109. Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 110. Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 111. Myriad Genetics, Inc. Recent Development
    Table 112. OPKO Health, Inc. Company Detail
    Table 113. OPKO Health, Inc. Business Overview
    Table 114. OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 115. OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 116. OPKO Health, Inc. Recent Development
    Table 117. QIAGEN N.V. Company Detail
    Table 118. QIAGEN N.V. Business Overview
    Table 119. QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Product
    Table 120. QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024) & (US$ Million)
    Table 121. QIAGEN N.V. Recent Development
    Table 122. Research Programs/Design for This Report
    Table 123. Key Data Information from Secondary Sources
    Table 124. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Next-Generation Gynecological Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Type: 2023 VS 2030
    Figure 3. Ovarian Cancer Diagnosis Features
    Figure 4. Cervical Cancer Diagnosis Features
    Figure 5. Uterine Cancer Diagnosis Features
    Figure 6. Global Next-Generation Gynecological Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Application: 2023 VS 2030
    Figure 8. Hospitals Case Studies
    Figure 9. Clinics Case Studies
    Figure 10. Others Case Studies
    Figure 11. Next-Generation Gynecological Cancer Diagnostics Report Years Considered
    Figure 12. Global Next-Generation Gynecological Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Next-Generation Gynecological Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region: 2023 VS 2030
    Figure 15. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players in 2023
    Figure 16. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue in 2023
    Figure 18. North America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2019-2030)
    Figure 20. United States Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Canada Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2019-2030)
    Figure 24. Germany Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. France Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. U.K. Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Italy Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Russia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Nordic Countries Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2019-2030)
    Figure 32. China Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Japan Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. South Korea Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Southeast Asia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. India Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Australia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Latin America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2019-2030)
    Figure 40. Mexico Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Brazil Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2019-2030)
    Figure 44. Turkey Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Quest Diagnostics Incorporated Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 47. Thermo Fisher Scientific Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 48. Agilent Technologies, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 49. Invitae Corporation Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 50. Konica Minolta, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 51. BGI Genomics Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 52. CENTOGENE N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 53. Fulgent Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 54. Illumina, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 55. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 56. Laboratory Corporation of America Holdings Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 57. ARUP Laboratories Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 58. Myriad Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 59. OPKO Health, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 60. QIAGEN N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2019-2024)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Lymphoma Therapy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-10S14319
Sun May 19 00:00:00 UTC 2024

Add to Cart

Global Gene Therapy on Cancer Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-3X14503
Sun May 19 00:00:00 UTC 2024

Add to Cart

Global Internal Radiotherapy Devices Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-10C14318
Sun May 19 00:00:00 UTC 2024

Add to Cart

Global Remote Afterloading System Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-34B7845
Sun May 19 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions